崔冰，1978年生，籍贯山西，肿瘤药理学家，药物研究所研究员，博士生导师。1996年考入中国药科大学药理学专业，2001年获得学士学位。2001-2004年在中国药科大学药理学攻读硕士学位，从事心血管药理学研究。2004-2007年在北京协和医学院药物研究所药理学攻读博士学位，从事分子免疫药理学研究。2007年进入美国加州大学圣迭戈分校（UCSD）肿瘤中心进行博士后研究工作，主要研究肿瘤生物学。2012年升为助理项目科学家。2015年9月获聘研究员，2022年任所长助理。

肿瘤转移、肿瘤干性维持的分子生物学机制及药靶鉴定；非编码RNA的肿瘤生物学作用；代谢紊乱相关慢性病发病机制及药靶鉴定，主要涉及肿瘤、纤维化等疾病。

1. Liu SS*#, Lv XX#, Wei XP, Liu C, Li Q, Min JL, Hua F, Zhang XW, Li K, Li PP, Xiao Y, Hu ZW, Cui B*. TRIB3‒GSK-3 interaction promotes lung fibrosis and serves as a potential therapeutic target. Acta Pharm Sin B 2021, Oct; 11(10):3105-3119. (IF =11.413)

2. Yu JM#, Sun W#, Wang ZH#, Liang X, Hua F, Li K, Lv XX, Zhang XW, Liu YY, Yu JJ, Liu SS, Shang S, Wang F, Yang ZN, Zhao CX, Hou XY, Li PP, Huang B, Cui B*, Hu ZW*. TRIB3 Supports Breast Cancer Stemness by Suppressing FOXO1 Degradation and Enhancing SOX2 Transcription. Nat Commun 2019;10(1):5720, (IF =12.121)

3. Sun W#, Yang ZN#, Lin H, Liu M, Zhao CX, Hou XY, Hu ZW, Cui B*. Improvement in affinity and thermostability of a fully human antibody against interleukin-17A by yeast-display technology and CDR grafting. Acta Pharm Sin B 2019; 9(5):960-972. (IF=7.097)

4. Cui B, Eyers PA, Dobens LL, Tan NS, Mace PD, Link WA, Kiss-Toth E , Keeshan K, Nakamura T, Pear WS, Feseha Y, Johnston J, Carracedo A, Scheideler M, llyas Z, Bauer RC, Erusalimsky JD, Grzesik D, Salamanca-Viloria J , Lv XX, Jin YS, Li K, Velasco G, Shang S, Lizcano JM, Zhang XW, Zhou JC, Yu JJ, Hua F, Wang F, Liu SS, Yu JM, Hu ZW#. Highlights of the 2nd International Symposium on Tribbles and Diseases: Tribbles tremble in therapeutics for immunity, metabolism, fundamental cell biology and cancer. Acta Pharm Sin B 2019;9(2):443-454. (IF =7.097)

5. Cui B#, Ghia EM#, Chen L#, Rassenti LZ, Zhang L, Neuberg DS, Wierda WG, Keating MJ, Rai KR, Kay NE, Brown JR, Byrd JC, Gribben JG, Greaves AW, Kipps TJ*. High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia. Blood 2016 Dec; 128(25):2931-2940. (IF=13.164)

6. Zhang S#, Cui B#, Lai H, Christina W, Liu G, Widhopf GF II , Wu RR, Lao F, Schwab R, Carson D, Kipps TJ*. Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy. Proc Natl Acad Sci U S A 2014 Dec; 111(48):17266-71. (IF=9.674, C100)

7. Cui B#, Chen L#, Chen G, Lei B, Mraz M, Salcedo M, Rassenti L, Messer M, Calin GA, Croce CM, Kipps TJ*. MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. Blood 2014 Jul; 124(4):546-54. (IF=10.452, C100)

8. Widhopf II GF#, Cui B#, Ghia, EM, Chen LG, Messer K, Shen ZX, Briggs SP, Croce CM, Kipps TJ*, ROR1 Can Interact With TCL1 And Enhance Leukemogenesis in Eµ-TCL1 Transgenic Mice. Proc Natl Acad Sci U S A 2014 Jan;111(2):793-798. (IF=9.674)

9. Cui B#, Zhang SP#, Chen LG, Yu JQ, Widhopf II GF, Fecteau JF, Rassenti LZ, Kipps TJ*, Targeting ROR1 Inhibits Epithelial-Mesenchymal Transition and Metastasis. Cancer Research 2013 Jun;73(12):3649-60. (IF=9.284, C100)

10. Yang HZ#, Cui B#, Liu HZ, Chen ZR, Yan HM, Hua F, Hu ZW*. Targeting TLR2 attenuates pulmonary inflammation and fibrosis by reversion of suppressive immune microenvironment. J Immunol. 2009 Jan;182(1):692-702. (IF=5.646, F1000)